Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells

He, Mi; Soni, Bhavesh; Schwalie, Petra C; Hüsser, Tamara; Waltzinger, Caroline; De Silva, Duvini; Prinz, Ylva; Krümpelmann, Laura; Calabro, Samuele; Matos, Ines; Trumpfheller, Christine; Bacac, Marina; Umaña, Pablo; Levesque, Mitchell P; Dummer, Reinhard; van den Broek, Maries; Gasser, Stephan

doi:10.1136/jitc-2021-004268

Citations

Citation copied

He, M., Soni, B., Schwalie, P. C., Hüsser, T., Waltzinger, C., De Silva, D., Prinz, Y., Krümpelmann, L., Calabro, S., Matos, I., Trumpfheller, C., Bacac, M., Umaña, P., Levesque, M. P., Dummer, R., van den Broek, M., & Gasser, S. (2022). Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells. Journal for ImmunoTherapy of Cancer, 10(6), e004268. https://doi.org/10.1136/jitc-2021-004268

Abstract

BackgroundDendritic cells (DCs) are professional antigen presenting cells that initiate immune defense to pathogens and tumor cells. Human tumors contain only few DCs that mostly display a non-activated phenotype. Hence, activation of tumor-associated DCs may improve efficacy of cancer immunotherapies. Toll-like receptor (TLR) agonists and interferons are known to promote DC maturation. However, it is unclear if DCs in human tumors respond to activation signals and which stimuli induce the optimal activation of human tumor DCs.Methods